33,940 Shares in Sarepta Therapeutics, Inc. $SRPT Purchased by State of New Jersey Common Pension Fund D

Posted by Geri Gentry on May 12th, 2026

State of New Jersey Common Pension Fund D bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 33,940 shares of the biotechnology company’s stock, valued at approximately $730,000.

Several other hedge funds and other institutional investors have also bought and sold shares of SRPT. iSAM Funds UK Ltd purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at about $25,000. Ancora Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter. Allworth Financial LP lifted its position in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the period. Parallel Advisors LLC lifted its position in Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,256 shares during the period. Finally, Atlantic Union Bankshares Corp purchased a new stake in Sarepta Therapeutics in the third quarter worth approximately $48,000. Institutional investors own 86.68% of the company’s stock.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the sale, the director owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

Sarepta Therapeutics Stock Down 2.8%

SRPT opened at $19.40 on Tuesday. The firm’s 50 day simple moving average is $19.83 and its two-hundred day simple moving average is $20.25. The company has a market capitalization of $2.05 billion, a PE ratio of -20.21, a PEG ratio of 0.29 and a beta of 0.26. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $44.14. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($3.42) EPS. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.89 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Weiss Ratings raised Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, March 26th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $30.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and an average target price of $27.71.

Get Our Latest Stock Report on Sarepta Therapeutics

Sarepta Therapeutics Profile

(Free Report)

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.